Novo Nordisk Exposed to U.S. Tariff Risks

about 1 month ago

Chloe Millay

"Yeah, they actually haven't, except for one name in particular, which is Novo Nordisk. So, Trump announced a rate, say, 100% tariff on branded pharmaceuticals... And Novo Nordisk was the worst hit this morning. And that might be because it makes the main ingredient for Zempick and Wegovi, which obviously it's two blockbuster drugs in Denmark."

Novo Nordisk is highlighted as being particularly vulnerable to the new U.S. tariffs on branded pharmaceuticals. Its exposure is attributed to its reliance on ingredients for blockbuster drugs and the lack of domestic U.S. manufacturing facilities. Investors should take note of this negative catalyst as it may warrant caution in the short-term trading environment.

Related Stocks